Entropy Neurodynamics (ASX:ENP) has completed enrolment of the first cohort in its clinical trial of TRP 8803, an intravenously infused formulation of psilocin, marking a key operational milestone in the company’s push to develop new treatments for binge eating disorder.

Botanix Pharmaceuticals (ASX:BOT) has entered 2026 with strong commercial momentum, reporting rapid growth in prescriptions and revenue for Sofdra, its FDA-approved treatment for primary axillary hyperhidrosis, while positioning the company for improved margins and platform expansion

A new Australian study suggests that a simple blood test could help doctors better identify which head and neck cancer patients are most likely to experience a relapse after treatment.

Australian company Vaxxas has been selected as part of an international consortium to help strengthen Europe’s preparedness for future seasonal and pandemic influenza threats, securing a place in a competitive European Union tender that could unlock up to $250 million in development funding.

CLINUVEL Pharmaceuticals (ASX:CUV) has reported its strongest December half-year revenue on record, underscoring what it describes as the resilience of its commercial platform and the disciplined execution of its long-term growth strategy.

Immutep (ASX:IMM) is entering an important phase of its development journey, as rising research spending and expanding clinical trials are reshaping both its financial results and its strategic outlook.

Neurizon Therapeutics (ASX:NUZ) has entered the second half of financial year 2026 in an acceleration phase, advancing its lead drug candidate while strengthening the financial and strategic foundations needed to bring it into late-stage development.

Acrux has returned to profitability for the first half of the 2026 financial year, reporting a significant improvement in performance as recently launched products delivered their first full revenue period.

Imugene (ASX:IMU) has reported a half-year shaped by tighter spending, renewed strategic focus and advancing clinical progress, as the company works to position its lead cell therapy program for the next stage of development.

The initiative is calling for expressions of interest from Australian small and medium enterprises, including start-ups and research spin-offs, that are developing medical devices to prevent, diagnose, treat, or manage heart disease and complications linked to both type 1 and type 2 diabetes.

Radiopharm Theranostics (ASX:RAD) has entered a significant new phase in its oncology program, announcing that the first patient has been dosed in a First-In-Human Phase 1/2a clinical trial of its experimental radiotherapeutic candidate, 177Lu BetaBart, also known as RV-01.

RNA therapy company PYC Therapeutics (ASX:PYC) has updated investors, confirming that it has concentrated on advancing its portfolio of first-in-class drug candidates, each intended to address the root cause of monogenic disorders.

Argent BioPharma (ASX:RGT) has marked a significant commercial step forward with the arrival of its largest-ever shipment of CannEpil in Ireland, signalling both expanding European market traction and the company’s growing operational scale.

Tetratherix (ASX:TTX) has released its half-year results for the 2026 financial year, with management saying the business remains on track across operations, finances and research as it moves from a research-focused company toward commercial growth.

Australia’s life sciences sector is set for a stronger, more coordinated innovation pipeline following a new national partnership between industry body AusBiotech and biomedical venture creator Proto Axiom.

Australia’s medical technology sector will take centre stage in May when AusBiotech brings its flagship AusMedtech conference to Perth for the first time.

CSL has taken another step in its push to expand its portfolio of innovative therapies, announcing a new licensing agreement with Eli Lilly that could broaden the future reach of its monoclonal antibody candidate, clazakizumab.